Targeting JAK-STAT signal transduction pathways in human carcinomas

Paper Details

Review Paper 01/08/2013
Views (256) Download (10)

Targeting JAK-STAT signal transduction pathways in human carcinomas


Cancer is the second most common cause of death in the United States and the leading cause of deaths worldwide and thus remains a global problem to the human population. Since the discovery of the JAK-STAT pathway over two decades ago, research investigations have clearly demonstrated that the JAK-STAT pathway plays a major role in many biological processes including proliferation, immunity, cellular activation, and differentiation to name just a few. While the JAK-STAT pathway is indispensable for normal cellular functions, it was also discovered that abnormal activation of the JAK-STAT signaling pathway significantly contributes to the formation and progression of many human carcinomas. By examining dysfunctional intracellular activation events researchers may identify specific molecular regulators of disease and develop interventions to prevent and treat particular diseases. JAK-STAT signaling mechanisms during pathogenesis and cancer development are continually being explored for potential therapeutic benefit. The following review explores novel molecular therapeutic strategies.


American Cancer Society. 2013. Cancer facts & figures 2013. Atlanta: American Cancer Society.

Anzick SL, Trent JM. 2002. Role of genomics in identifying new targets for cancer therapy. Oncology 16, 7-13.

Aringer M, Cheng A, Nelson JW, Chen M, Sudarshan C, Zhou YJ, O’Shea JJ. 1999. Janus kinases and their role in growth and disease. Life Sciences 64, 2173-2186.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y. 2013. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. International Journal of Oncology 43, 219-227.

Baselga J, Hammond LA. 2002.  HER-targeted tyrosine-kinase inhibitors. Oncology 63, 6-16.

Bubendorf L. 2001. High-throughput microarray technologies: from genomics to clinics. European Urology 40, 231-238

Chen X, Du Y, Nan J, Zhang X, Qin X, Wang Y, Hou J, Wang Q, Yang J. 2013. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. Public Library of Science One 8, e63697.

Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. 2004. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. International Journal of Cancer 108, 665-671.

Darnell JE. 2002. Transcription factors as targets for cancer therapy. Nature Reviews Cancer 2, 740-749.

Darnell JE, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and  other extracellular  signaling proteins. Science 264, 1415-1421

Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. 2002. Stat3 activation in prostatic carcinomas. Prostate 51, 241-246.

Flowers LO. 2012. SOCS negative regulation of the JAK-STAT pathway. International Journal of Biosciences 2, 13-23.

Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SM, Subramaniam PS. 2004. Characterization of a peptide inhibitor of JAK2 that mimics SOCS-1 function. Journal of Immunology 172, 7510-7518.

Flowers LO, Subramaniam PS, Johnson HM. 2005. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 24, 2114-2120.

Imada K, Leonard WJ. 2000. The Jak-Stat pathway. Molecular Immunology 37, 1-11

Kaushal M, Chorawala M. 2012. The JAK/STAT signaling pathway. International Journal of Advanced Research in Pharmaceutical & Biosciences 2, 363-385.

Kawakami Y, Yaguchi T, Sumimoto H, Kudo-Saito C, Iwata-Kajihara T, Nakamura S, Tsujikawa T, Park JH, Popivanova BK, Miyazaki J, Kawamura N. 2013. Improvement of cancer immunotherapy by combining molecular targeted therapy. Frontiers in Oncology 3, 136.

Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. 2004. Diet, nutrition and the prevention of cancer. Public Health Nutrition 7, 187-200.

Kim MJ, Nam HJ, Kim HP, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. 2013. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Letters 335, 145-152.

Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1-24.

Kotenko SV, Pestka S. 2000. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19, 2557-2565.

Kumar G, Gupta S, Wang S, Nel A. 1994. Involvement of Janus kinases, p52shc, Raf-1, and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line. Journal of Immunology 153, 4436-4447.

Leonard WJ, O’Shea JJ. 1998. Jaks and STATs:biological implications. Annual Review of Immunology 16, 293-322.

Li W. 2008. Canonical and non-canonical JAK-STAT signaling. Trends in Cell Biology 18, 545-551.

May TS. 2003. Gleevec: tailoring to fit. Drug Discovery Today 8, 188-189.

Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. 2002. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Research 62, 6659-6666.

Nakagawa H. 2013. Prostate cancer genomics by high-throughput technologies: genome-wide association study and sequencing analysis. Endocrine Related Cancer 20, R171-R181.

Sakai I, Kraft A. 1997. The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. Journal of Biological Chemistry 272, 12350-12358

Schweiger MR, Barmeyer C, Timmermann B. 2013. Genomics and epigenomics: new promises of personalized medicine for cancer patients. Briefings in Functional Genomics 12, 1-11.

Shawver LK, Slamon D, Ullrich A. 2002. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123

Spiekermann K, Faber F, Voswinckel R, Hiddemann W. 2002. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Experimental Hematology 30, 767-773.

Stark GR, Darnell JE. 2012. The JAK-STAT pathway at twenty. Immunity 36, 503-514.

Verma A, Kambhampati S, Parmar S, Platanias LC. 2003. Jak family of kinases in cancer. Cancer Metastasis Reviews 22, 423-434.

Yan S, Li Z, Thiele CJ. 2013. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in neuroblastoma and pediatric sarcomas In vitro and In vivo. Oncotarget 3, 433-445.

Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q, Cao P. 2013. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells. Cancer Letters 328, 243-251.

You Z, Xu D, Ji J, Guo W, Zhu W, He J. 2012. JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma. Clinical and Translational Oncology 14, 143-149

Yu C, Meyer D, Campbell G, Larner A, Carter-Su C, Schwartz J, Jove R. 1995. Enhanced DNA- binding  activity  of  a  Stat3-related  protein  in  cells transformed by the Src oncoprotein. Science 269, 81-83.

Zhang H, Zhang D, Luan X, Xie G, Pan X. 2010. Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells. Journal of International Medical Research 38, 1673-1681

Zhang P, Gao WY, Turner S, Ducatman BS. 2003. Gleevec  (STI-571)  inhibits  lung  cancer  cell growth (A549) and potentiates the cisplatin effect in vitro. Molecular Cancer 2.